BERINERT

Type I and

II hereditary angioedema (HFA).

Treatment and prevention before acute outbreak intervention.

For patients with known allergic or anaphylactic reactions, the laboratory laboratory for the detection of the drug is a laboratory for the detection of the drug.

Pharmacotherapeutic group

C1 inhibitor, plasma derivatives, ATC code: B06AC01 The C1 inhibitor is a plasma glycoprotein with a molecular weight of 105 kD and a 40% carbohydrate portion.

C1 inhibitor is a human plasma inhibitor of approximately 240 mg/l.

Human plasma, placenta, liver cells, monocytes and platelets also contain C1 inhibitor esterase.

C1 inhibitor esterase belongs to the human plasma serine protease (serpine) inhibitor system as well as other proteins: antithrombine III, alpha-2 antiplasmine, alpha-1-antitrypsin and others.

Under physiological conditions, the C1 inhibitor esterase inhibits the conventional complement pathway by inactivating the active enzymatic components C1s and C1r.

The active enzyme forms with l♥inhibitor a psychonergic complex with the enzyme-like enzyme.

• Very common: > 1/10.

• Common: > 1/100 and 1/1,000 and 1/10,000 and <1/1,000.

• Very rare: < 1/10,000 (including isolated cases) Adverse reactions with BERINERT are rare.

Organ system class Very common Uncommon Uncommon Uncommon Very rare Vascular disorders Thrombosis development General disorders and administration site abnormalities Fever, injection site reactions Immune system disorders Allergic or anaphylactic reactions (e.g. tachycardia, hyper - or hypotension, redness, urticaria, dyspnoea, headache, dizziness, nausea) Choc When attempting to treat with high doses of BERINERT prophylaxis or anaphylactic type reactions (e.g. tachycardia, hyper - or hypotensive, reddensal, urticaria, dyspnoea, headache, vertigo, nausea) Choc * When attempting to treat high doses of BERINERT in prophylaxis or curative hair leakage syndrome before, during or after cardiac surgery with use of the extracorporemal circulation (eal adverse.